Compass Therapeutics filed Form S-3 with the SEC on August 13, 2025, with Jefferies, Piper Sandler, and Guggenheim Securities acting as joint bookrunning managers.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Compass Therapeutics filed Form S-3 with the SEC on August 13, 2025, with Jefferies, Piper Sandler, and Guggenheim Securities acting as joint bookrunning managers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Securities and Exchange Commission
government agency of the Philippines
-
Piper Sandler Companies
American financial services company
Related events
- First Merchants Corporation is pursuing an offering, with Keefe, Bruyette & Woods appointed as the sole book-running manager, requiring filings with the SEC.
- A company filed reports with the Securities and Exchange Commission and held a conference call led by David Wilson and Greg on June 4, 2026.
- Evolution Petroleum Corporation, Inc. filed an offering with the SEC, with ROTH Capital Partners serving as the sole book-running manager. The bookrunner's office is located in Newport Beach.
Coverage
Newest first; wire copies grouped- GlobeNewswireCompass Therapeutics Announces Proposed Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmace